arrow
S

Simon Rothenfußer

Ludwig Maximilian University of Munich
H指数:47
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory

幼稚样记忆T细胞的代谢静息状态先于并维持抗原特异性T细胞记忆

2026-02-240
OAAI
Signal Transducer and Activator of Transcription 3 (STAT3) Variant p.K709N Causes Hyper-IgE Syndrome Likely by Impaired STAT3-Dimer Formation

信号转导子和转录激活因子3(STAT3)变体p.K709N导致高IgE综合征,可能通过抑制STAT3二聚体形成。

2025-07-280
OAAI
Clinical and Molecular Characteristics of X-linked Agammaglobulinemia Patients 55 Years or Older

X-连锁无丙种球蛋白血症患者55岁及以上人群的临床及分子特征

2025-06-240
PRE
Interferon- induced activation of dendritic cells and monocytes by yellow fever vaccination correlates with early antibody responses

黄热病疫苗接种诱导树突状细胞和单核细胞的干扰素激活与早期抗体反应相关

2025-05-070
OA
Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia

先天性肾上腺皮质增生症中反向昼夜节律糖皮质激素治疗免疫表型的影响

2025-02-100
OA
Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells
2024-04-010
OAAI
Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection
2024-02-240
OAAI
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis
IMMUNITY
IF26.3
2023-01-0137
OA
A High-Throughput Yellow Fever Neutralization Assay
2022-06-2911
OAAI
Impaired function and delayed regeneration of dendritic cells in COVID-19
2021-10-0659
OAAI
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis
2021-07-2926
PRE
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

带有c-x-c趋化因子受体6型的T细胞可增强胰腺肿瘤的过继细胞疗法

2021-06-03107
OAAI
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner
2021-04-3017
OAAI
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma
2020-07-1114
OAAI